08:16:01 root         INFO     Skipping 27599
08:16:01 root         INFO     Skipping 30449
08:16:01 root         INFO     Skipping 14315
08:16:01 root         INFO     Skipping 7566
08:16:01 root         INFO     Skipping 804
08:16:01 root         INFO     Skipping 12106
08:16:01 root         INFO     Skipping 8034
08:16:01 root         INFO     Skipping 7901
08:16:01 root         INFO     Skipping 20157
08:16:01 root         INFO     Skipping 6950
08:16:01 root         INFO     Skipping 15026
08:16:01 root         INFO     Skipping 19993
08:16:01 root         INFO     Skipping 21569
08:16:01 root         INFO     Skipping 23030
08:16:01 root         INFO     Skipping 206
08:16:01 root         INFO     Skipping 16046
08:16:01 root         INFO     Skipping 16140
08:16:01 root         INFO     Skipping 16037
08:16:01 root         INFO     Skipping 43
08:16:01 root         INFO     Skipping 225
08:16:01 root         INFO     Skipping 37711
08:16:01 root         INFO     Skipping 34699
08:16:01 root         INFO     Skipping 19021
08:16:01 root         INFO     Skipping 18495
08:16:01 root         INFO     Skipping 222
08:16:01 root         INFO     Skipping 5602
08:16:01 root         INFO     Skipping 16027
08:16:01 root         INFO     Skipping 21499
08:16:01 root         INFO     Skipping 2698
08:16:01 root         INFO     Skipping 27867
08:16:01 root         INFO     Skipping 24224
08:16:01 root         INFO     Skipping 21563
08:16:01 root         INFO     Skipping 24227
08:16:01 root         INFO     Skipping 17224
08:16:01 root         INFO     Skipping 219
08:16:01 root         INFO     Skipping 23814
08:16:01 root         INFO     Skipping 15376
08:16:01 root         INFO     Skipping 19286
08:16:01 root         INFO     Skipping 28048
08:16:01 root         INFO     Skipping 543
08:16:01 root         INFO     Skipping 24233
08:16:01 root         INFO     Skipping 18735
08:16:01 root         INFO     Skipping 1066
08:16:01 root         INFO     Skipping 37680
08:16:01 root         INFO     Skipping 691
08:16:01 root         INFO     Skipping 677
08:16:01 root         INFO     Skipping 20141
08:16:01 root         INFO     Skipping 36151
08:16:01 root         INFO     Skipping 20319
08:16:01 root         INFO     Skipping 12400
08:16:01 root         INFO     Skipping 127
08:16:01 root         INFO     Skipping 20792
08:16:01 root         INFO     Skipping 17104
08:16:01 root         INFO     Skipping 24344
08:16:01 root         INFO     Skipping 19546
08:16:01 root         INFO     Skipping 15565
08:16:01 root         INFO     Skipping 13359
08:16:01 root         INFO     Skipping 17922
08:16:01 root         INFO     Skipping 22481
08:16:01 root         INFO     Skipping 20138
08:16:01 root         INFO     Skipping 119
08:16:01 root         INFO     Skipping 21188
08:16:01 root         INFO     Skipping 3016
08:16:01 root         INFO     Skipping 21525
08:16:01 root         INFO     Skipping 37694
08:16:01 root         INFO     Skipping 18710
08:16:01 root         INFO     Skipping 29332
08:16:01 root         INFO     Skipping 23100
08:16:01 root         INFO     Skipping 37725
08:16:01 root         INFO     Skipping 15633
08:16:01 root         INFO     Skipping 948
08:16:01 root         INFO     Skipping 30993
08:16:01 root         INFO     Skipping 22221
08:16:01 root         INFO     Skipping 22654
08:16:01 root         INFO     Skipping 35809
08:16:01 root         INFO     Skipping 35576
08:16:01 root         INFO     Skipping 37408
08:16:01 root         INFO     Skipping 7844
08:16:01 root         INFO     Skipping 20
08:16:01 root         INFO     Skipping 8022
08:16:01 root         INFO     Skipping 8032
08:16:01 root         INFO     Skipping 20605
08:16:01 root         INFO     Skipping 7838
08:16:01 root         INFO     Skipping 21497
08:16:01 root         INFO     Skipping 35572
08:16:01 root         INFO     Skipping 30425
08:16:01 root         INFO     Skipping 35517
08:16:01 root         INFO     Skipping 35524
08:16:01 root         INFO     Skipping 21522
08:16:01 root         INFO     Skipping 1325
08:16:01 root         INFO     Skipping 1079
08:16:01 root         INFO     Skipping 6973
08:16:01 root         INFO     Skipping 37495
08:16:01 root         INFO     Skipping 30405
08:16:01 root         INFO     Skipping 18767
08:16:01 root         INFO     Skipping 21521
08:16:01 root         INFO     Skipping 921
08:16:01 root         INFO     Skipping 27602
08:16:01 root         INFO     Skipping 21335
08:16:01 root         INFO     Skipping 30444
08:16:01 root         INFO     Skipping 1363
08:16:01 root         INFO     Skipping 9488
08:16:01 root         INFO     Skipping 24230
08:16:01 root         INFO     Skipping 2696
08:16:01 root         INFO     Skipping 37705
08:16:01 root         INFO     Skipping 33752
08:16:01 root         INFO     Skipping 37731
08:16:01 root         INFO     Skipping 37740
08:16:01 root         INFO     Skipping 9427
08:16:01 root         INFO     Skipping 19880
08:16:01 root         INFO     Skipping 632
08:16:01 root         INFO     Skipping 39007
08:16:01 root         INFO     Skipping 551
08:16:01 root         INFO     Skipping 37304
08:16:01 root         INFO     Skipping 20115
08:16:01 root         INFO     Skipping 13362
08:16:01 root         INFO     Skipping 7333
08:16:01 root         INFO     Skipping 21423
08:16:01 root         INFO     Skipping 17653
08:16:01 root         INFO     Skipping 21152
08:16:01 root         INFO     Skipping 16031
08:16:01 root         INFO     Skipping 27074
08:16:01 root         INFO     Skipping 255
08:16:01 root         INFO     Skipping 431
08:16:01 root         INFO     Skipping 19290
08:16:01 root         INFO     Skipping 33954
08:16:01 root         INFO     Skipping 22921
08:16:01 root         INFO     Skipping 26556
08:16:01 root         INFO     Skipping 167
08:16:01 root         INFO     Skipping 15884
08:16:01 root         INFO     Skipping 30382
08:16:01 root         INFO     Skipping 30450
08:16:01 root         INFO     Skipping 27626
08:16:01 root         INFO     Skipping 37748
08:16:01 root         INFO     Skipping 715
08:16:01 root         INFO     Skipping 18734
08:16:01 root         INFO     Skipping 9485
08:16:01 root         INFO     Skipping 24231
08:16:01 root         INFO     Skipping 6221
08:16:01 root         INFO     Skipping 15392
08:16:01 root         INFO     Skipping 14466
08:16:01 root         INFO     Skipping 15025
08:16:01 root         INFO     Skipping 19760
08:16:01 root         INFO     Skipping 37095
08:16:01 root         INFO     Skipping 13863
08:16:01 root         INFO     Skipping 7355
08:16:01 root         INFO     Skipping 8042
08:16:01 root         INFO     Skipping 23802
08:16:01 root         INFO     Skipping 282
08:16:01 root         INFO     Skipping 7316
08:16:01 root         INFO     Skipping 16040
08:16:01 root         INFO     Skipping 7922
08:16:01 root         INFO     Skipping 16041
08:16:01 root         INFO     Skipping 28101
08:16:01 root         INFO     Skipping 3410
08:16:01 root         INFO     Skipping 7121
08:16:01 root         INFO     Skipping 17116
08:16:01 root         INFO     Skipping 20034
08:16:01 root         INFO     Skipping 6918
08:16:01 root         INFO     Skipping 22037
08:16:01 root         INFO     Skipping 14373
08:16:01 root         INFO     Skipping 13794
08:16:01 root         INFO     Skipping 13964
08:16:01 root         INFO     Skipping 6930
08:16:01 root         INFO     Skipping 19978
08:16:01 root         INFO     Skipping 14069
08:16:01 root         INFO     Skipping 14111
08:16:01 root         INFO     Skipping 6931
08:16:01 root         INFO     Skipping 14021
08:16:01 root         INFO     Skipping 37180
08:16:01 root         INFO     Skipping 35130
08:16:01 root         INFO     Skipping 19684
08:16:01 root         INFO     Skipping 28292
08:16:01 root         INFO     Skipping 30335
08:16:01 root         INFO     Skipping 14867
08:16:01 root         INFO     Skipping 23669
08:16:01 root         INFO     Skipping 6793
08:16:01 root         INFO     Skipping 15440
08:16:01 root         INFO     Skipping 23588
08:16:01 root         INFO     Skipping 10156
08:16:01 root         INFO     Skipping 30046
08:16:01 root         INFO     Skipping 39476
08:16:01 root         INFO     Skipping 37727
08:16:01 root         INFO     Skipping 33096
08:16:01 root         INFO     Skipping 32423
08:16:01 root         INFO     Skipping 30658
08:16:01 root         INFO     Skipping 19870
08:16:01 root         INFO     Skipping 15962
08:16:01 root         INFO     Skipping 702
08:16:01 root         INFO     Skipping 39478
08:16:01 root         INFO     Skipping 30435
08:16:01 root         INFO     Skipping 9445
08:16:01 root         INFO     Skipping 24173
08:16:01 root         INFO     Skipping 35554
08:16:01 root         INFO     Skipping 18733
08:16:01 root         INFO     Skipping 3962
08:16:01 root         INFO     Skipping 26659
08:16:01 root         INFO     Skipping 32135
08:16:01 root         INFO     Skipping 27843
08:16:01 root         INFO     Skipping 17658
08:16:01 root         INFO     Skipping 27186
08:16:01 root         INFO     Skipping 6922
08:16:01 root         INFO     Skipping 7317
08:16:01 root         INFO     Skipping 37607
08:16:01 root         INFO     Skipping 19748
08:16:01 root         INFO     Skipping 14979
08:16:01 root         INFO     Skipping 28256
08:16:01 root         INFO     Skipping 15000
08:16:01 root         INFO     Skipping 15725
08:16:01 root         INFO     Skipping 21561
08:16:01 root         INFO     Skipping 23098
08:16:01 root         INFO     Skipping 30469
08:16:01 root         INFO     Skipping 37819
08:16:01 root         INFO     Skipping 27605
08:16:01 root         INFO     Skipping 24799
08:16:01 root         INFO     Skipping 35571
08:16:01 root         INFO     Skipping 18750
08:16:01 root         INFO     Skipping 21564
08:16:01 root         INFO     Skipping 695
08:16:01 root         INFO     Skipping 619
08:16:01 root         INFO     Skipping 21566
08:16:01 root         INFO     Skipping 18746
08:16:01 root         INFO     Skipping 30470
08:16:01 root         INFO     Skipping 37747
08:16:01 root         INFO     Skipping 35726
08:16:01 root         INFO     Skipping 35708
08:16:01 root         INFO     Skipping 35705
08:16:01 root         INFO     Skipping 35727
08:16:01 root         INFO     Skipping 37743
08:16:01 root         INFO     Skipping 24229
08:16:01 root         INFO     Skipping 37748
08:16:01 root         INFO     Skipping 19879
08:16:01 root         INFO     Skipping 717
08:16:01 root         INFO     Skipping 35728
08:16:01 root         INFO     Skipping 37820
08:16:01 root         INFO     Skipping 30473
08:16:01 root         INFO     Skipping 37744
08:16:01 root         INFO     Skipping 28313
08:16:01 root         INFO     Skipping 37749
08:16:01 root         INFO     Skipping 15948
08:16:01 root         INFO     Skipping 35707
08:16:01 root         INFO     Skipping 35706
08:16:01 root         INFO     Skipping 35704
08:16:01 root         INFO     Skipping 18740
08:16:01 root         INFO     Skipping 18736
08:16:01 root         INFO     Skipping 7887
08:16:01 root         INFO     Skipping 15551
08:16:01 root         INFO     Skipping 35562
08:16:01 root         INFO     Skipping 9423
08:16:01 root         INFO     Skipping 1519
08:16:01 root         INFO     Skipping 35489
08:16:01 root         INFO     Skipping 20880
08:16:01 root         INFO     Skipping 37235
08:16:01 root         INFO     Skipping 15882
08:16:01 root         INFO     Skipping 1169
08:16:01 root         INFO     Skipping 9463
08:16:01 root         INFO     Skipping 37685
08:16:01 root         INFO     Skipping 809
08:16:01 root         INFO     Skipping 9421
08:16:01 root         INFO     Skipping 30397
08:16:01 root         INFO     Skipping 37735
08:16:01 root         INFO     Skipping 30394
08:16:01 root         INFO     Skipping 30448
08:16:01 root         INFO     Skipping 27614
08:16:01 root         INFO     Skipping 35527
08:16:01 root         INFO     Skipping 37416
08:16:01 root         INFO     Skipping 37709
08:16:01 root         INFO     Skipping 27649
08:16:01 root         INFO     Skipping 35546
08:16:01 root         INFO     Skipping 1098
08:16:01 root         INFO     Skipping 21488
08:16:01 root         INFO     Skipping 37674
08:16:01 root         INFO     Skipping 37706
08:16:01 root         INFO     Skipping 37713
08:16:01 root         INFO     Skipping 918
08:16:01 root         INFO     Skipping 24210
08:16:01 root         INFO     Skipping 37728
08:16:01 root         INFO     Skipping 35555
08:16:01 root         INFO     Skipping 35556
08:16:01 root         INFO     Skipping 892
08:16:01 root         INFO     Skipping 38045
08:16:01 root         INFO     Skipping 829
08:16:01 root         INFO     Skipping 30468
08:16:01 root         INFO     Skipping 24186
08:16:01 root         INFO     Skipping 24194
08:16:01 root         INFO     Skipping 37693
08:16:01 root         INFO     Skipping 30429
08:16:01 root         INFO     Skipping 1249
08:16:01 root         INFO     Skipping 30434
08:16:01 root         INFO     Skipping 24199
08:16:01 root         INFO     Skipping 37688
08:16:01 root         INFO     Skipping 23853
08:16:01 root         INFO     Skipping 30456
08:16:01 root         INFO     Skipping 1036
08:16:01 root         INFO     Skipping 30436
08:16:01 root         INFO     Skipping 37690
08:16:01 root         INFO     Skipping 36428
08:16:01 root         INFO     Skipping 37721
08:16:01 root         INFO     Skipping 27646
08:16:01 root         INFO     Skipping 24187
08:16:01 root         INFO     Skipping 35551
08:16:01 root         INFO     Skipping 925
08:16:01 root         INFO     Skipping 21570
08:16:01 root         INFO     Skipping 21536
08:16:01 root         INFO     Skipping 604
08:16:01 root         INFO     Skipping 21562
08:16:01 root         INFO     Skipping 21572
08:16:01 root         INFO     Skipping 17884
08:16:01 root         INFO     Skipping 235
08:16:01 root         INFO     Skipping 21487
08:16:01 root         INFO     Skipping 27644
08:16:01 root         INFO     Skipping 37722
08:16:01 root         INFO     Skipping 24175
08:16:01 root         INFO     Skipping 27637
08:16:01 root         INFO     Skipping 9424
08:16:01 root         INFO     Skipping 24181
08:16:01 root         INFO     Skipping 37676
08:16:01 root         INFO     Skipping 15912
08:16:01 root         INFO     Skipping 1004
08:16:01 root         INFO     Skipping 15922
08:16:01 root         INFO     Skipping 21523
08:16:01 root         INFO     Skipping 14489
08:16:01 root         INFO     Skipping 18756
08:16:01 root         INFO     Skipping 23549
08:16:01 root         INFO     Skipping 30414
08:16:01 root         INFO     Skipping 28735
08:16:01 root         INFO     Skipping 599
08:16:01 root         INFO     Skipping 24124
08:16:01 root         INFO     Skipping 24218
08:16:01 root         INFO     Skipping 19874
08:16:01 root         INFO     Skipping 21467
08:16:01 root         INFO     Skipping 30525
08:16:01 root         INFO     Skipping 24176
08:16:01 root         INFO     Skipping 15949
08:16:01 root         INFO     Skipping 27630
08:16:01 root         INFO     Skipping 27632
08:16:01 root         INFO     Skipping 606
08:16:01 root         INFO     Skipping 27629
08:16:01 root         INFO     Skipping 24228
08:16:01 root         INFO     Skipping 562
08:16:01 root         INFO     Skipping 21633
08:16:01 root         INFO     Skipping 24225
08:16:01 root         INFO     Skipping 18725
08:16:01 root         INFO     Skipping 21567
08:16:01 root         INFO     Skipping 27628
08:16:01 root         INFO     Skipping 12921
08:16:01 root         INFO     Skipping 47
08:16:01 root         INFO     Skipping 8101
08:16:01 root         INFO     Skipping 27936
08:16:01 root         INFO     Skipping 23089
08:16:01 root         INFO     Skipping 15911
08:16:01 root         INFO     Skipping 30472
08:16:01 root         INFO     Skipping 35703
08:16:01 root         INFO     Skipping 30475
08:16:01 root         INFO     Skipping 18739
08:16:01 root         INFO     Skipping 30378
08:16:01 root         INFO     Skipping 21
08:16:01 root         INFO     Skipping 24169
08:16:01 root         INFO     Skipping 27616
08:16:01 root         INFO     Skipping 546
08:16:01 root         INFO     Skipping 125
08:16:01 root         INFO     Skipping 432
08:16:01 root         INFO     Skipping 23572
08:16:01 root         INFO     Skipping 1
08:16:01 root         INFO     Skipping 10
08:16:01 root         INFO     Skipping 106
08:16:01 root         INFO     Skipping 804
08:16:01 root         INFO     Skipping 697
08:16:01 root         INFO     Skipping 37667
08:16:01 root         INFO     Skipping 24234
08:16:01 root         INFO     Skipping 34781
08:16:01 root         INFO     Skipping 44
08:16:01 root         INFO     Skipping 2434
08:16:01 root         INFO     Skipping 7307
08:16:01 root         INFO     Skipping 7280
08:16:01 root         INFO     Skipping 14197
08:16:01 root         INFO     Skipping 6929
08:16:01 root         INFO     Skipping 24223
08:16:01 root         INFO     Skipping 30412
08:16:01 root         INFO     Skipping 21230
08:16:01 root         INFO     Skipping 7124
08:16:01 root         INFO     Skipping 7516
08:16:01 root         INFO     Skipping 9231
08:16:01 root         INFO     Skipping 13222
08:16:01 root         INFO     Skipping 24928
08:16:01 root         INFO     Skipping 14466
08:16:01 root         INFO     Skipping 19685
08:16:01 root         INFO     Skipping 14008
08:16:01 root         INFO     Skipping 20480
08:16:01 root         INFO     Skipping 7126
08:16:01 root         INFO     Skipping 15792
08:16:01 root         INFO     Skipping 27571
08:16:01 root         INFO     Skipping 19109
08:16:01 root         INFO     Skipping 14066
08:16:01 root         INFO     Skipping 7103
08:16:01 root         INFO     Skipping 13479
08:16:01 root         INFO     Skipping 13475
08:16:01 root         INFO     Skipping 24237
08:16:01 root         INFO     Skipping 28365
08:16:01 root         INFO     Skipping 7118
08:16:01 root         INFO     Skipping 19909
08:16:01 root         INFO     Skipping 13664
08:16:01 root         INFO     Skipping 13467
08:16:01 root         INFO     Skipping 18743
08:16:01 root         INFO     Skipping 19881
08:16:01 root         INFO     Skipping 6970
08:16:01 root         INFO     Skipping 7286
08:16:01 root         INFO     Skipping 14047
08:16:01 root         INFO     Skipping 35569
08:16:01 root         INFO     Skipping 37741
08:16:01 root         INFO     Skipping 37697
08:16:01 root         INFO     Skipping 1453
08:16:01 root         INFO     Skipping 18818
08:16:01 root         INFO     Skipping 37745
08:16:01 root         INFO     Skipping 18836
08:16:01 root         INFO     Skipping 37441
08:16:01 root         INFO     Skipping 24207
08:16:01 root         INFO     Skipping 1483
08:16:01 root         INFO     Skipping 30395
08:16:01 root         INFO     Skipping 30432
08:16:01 root         INFO     Skipping 36969
08:16:01 root         INFO     Skipping 21533
08:16:01 root         INFO     Skipping 1352
08:16:01 root         INFO     Skipping 30390
08:16:01 root         INFO     Skipping 1149
08:16:01 root         INFO     Skipping 24202
08:16:01 root         INFO     Skipping 30389
08:16:01 root         INFO     Skipping 15891
08:16:01 root         INFO     Skipping 14488
08:16:01 root         INFO     Skipping 30528
08:16:01 root         INFO     Skipping 27597
08:16:01 root         INFO     Skipping 37737
08:16:01 root         INFO     Skipping 1557
08:16:01 root         INFO     Skipping 27609
08:16:01 root         INFO     Skipping 900
08:16:01 root         INFO     Skipping 21527
08:16:01 root         INFO     Skipping 1479
08:16:01 root         INFO     Skipping 30387
08:16:01 root         INFO     Skipping 980
08:16:01 root         INFO     Skipping 37703
08:16:01 root         INFO     Skipping 15304
08:16:01 root         INFO     Skipping 14781
08:16:01 root         INFO     Skipping 15528
08:16:01 root         INFO     Skipping 25120
08:16:01 root         INFO     Skipping 33803
08:16:01 root         INFO     Skipping 20476
08:16:01 root         INFO     Skipping 27502
08:16:01 root         INFO     Skipping 13456
08:16:01 root         INFO     Skipping 27390
08:16:01 root         INFO     Skipping 15813
08:16:01 root         INFO     Skipping 7320
08:16:01 root         INFO     Skipping 20668
08:16:01 root         INFO     Skipping 38937
08:16:01 root         INFO     Skipping 37417
08:16:01 root         INFO     Skipping 13038
08:16:01 root         INFO     Skipping 6932
08:16:01 root         INFO     Skipping 14978
08:16:01 root         INFO     Skipping 17045
08:16:01 root         INFO     Skipping 22385
08:16:01 root         INFO     Skipping 7853
08:16:01 root         INFO     Skipping 14026
08:16:01 root         INFO     Skipping 14923
08:16:01 root         INFO     Skipping 7288
08:16:01 root         INFO     Skipping 7538
08:16:01 root         INFO     Skipping 13451
08:16:01 root         INFO     Skipping 25009
08:16:01 root         INFO     Skipping 9452
08:16:01 root         INFO     Skipping 20118
08:16:01 root         INFO     Skipping 20475
08:16:01 root         INFO     Skipping 14602
08:16:01 root         INFO     Skipping 7291
08:16:01 root         INFO     Skipping 13457
08:16:01 root         INFO     Skipping 7345
08:16:01 root         INFO     Skipping 35752
08:16:01 root         INFO     Skipping 31489
08:16:01 root         INFO     Skipping 15674
08:16:01 root         INFO     Skipping 31189
08:16:01 root         INFO     Skipping 20084
08:16:01 root         INFO     Skipping 16020
08:16:01 root         INFO     Skipping 2009
08:16:01 root         INFO     Skipping 1773
08:16:01 root         INFO     Skipping 7337
08:16:01 root         INFO     Skipping 14910
08:16:01 root         INFO     Skipping 7339
08:16:01 root         INFO     Skipping 24976
08:16:01 root         INFO     Skipping 30360
08:16:01 root         INFO     Skipping 24315
08:16:01 root         INFO     Skipping 30361
08:16:01 root         INFO     Skipping 30358
08:16:01 root         INFO     Skipping 37191
08:16:01 root         INFO     Skipping 3129
08:16:01 root         INFO     Skipping 3052
08:16:01 root         INFO     Skipping 37932
08:16:01 root         INFO     Skipping 3125
08:16:01 root         INFO     Skipping 3109
08:16:01 root         INFO     Skipping 20056
08:16:01 root         INFO     Skipping 37778
08:16:01 root         INFO     Skipping 35587
08:16:01 root         INFO     Skipping 28452
08:16:01 root         INFO     Skipping 3320
08:16:01 root         INFO     Skipping 30367
08:16:01 root         INFO     Skipping 3048
08:16:01 root         INFO     Skipping 3072
08:16:01 root         INFO     Skipping 38049
08:16:01 root         INFO     Skipping 30366
08:16:01 root         INFO     Skipping 30368
08:16:01 root         INFO     Skipping 27956
08:16:01 root         INFO     Skipping 15709
08:16:01 root         INFO     Skipping 38047
08:16:01 root         INFO     Skipping 3137
08:16:01 root         INFO     Skipping 3085
08:16:01 root         INFO     Skipping 2042
08:16:01 root         INFO     Skipping 30374
08:16:01 root         INFO     Skipping 3064
08:16:01 root         INFO     Skipping 3286
08:16:01 root         INFO     Skipping 30362
08:16:01 root         INFO     Skipping 3309
08:16:01 root         INFO     Skipping 37826
08:16:01 root         INFO     Skipping 4972
08:16:01 root         INFO     Skipping 15790
08:16:01 root         INFO     Skipping 18747
08:16:01 root         INFO     Skipping 22401
08:16:01 root         INFO     Skipping 18711
08:16:01 root         INFO     Skipping 3123
08:16:01 root         INFO     Skipping 3296
08:16:01 root         INFO     Skipping 30617
08:16:01 root         INFO     Skipping 19614
08:16:01 root         INFO     Skipping 23295
08:16:01 root         INFO     Skipping 35818
08:16:01 root         INFO     Skipping 7531
08:16:01 root         INFO     Skipping 19559
08:16:01 root         INFO     Skipping 26784
08:16:01 root         INFO     Skipping 25775
08:16:01 root         INFO     Skipping 27321
08:16:01 root         INFO     Skipping 7234
08:16:01 root         INFO     Skipping 6914
08:16:01 root         INFO     Skipping 58455
08:16:01 root         INFO     Skipping 18113
08:16:01 root         INFO     Skipping 39880
08:16:01 root         INFO     Skipping 22565
08:16:01 root         INFO     Skipping 27877
08:16:01 root         INFO     Skipping 23176
08:16:01 root         INFO     Skipping 20510
08:16:01 root         INFO     Skipping 22316
08:16:01 root         INFO     Skipping 20813
08:16:01 root         INFO     Skipping 21209
08:16:01 root         INFO     Skipping 17932
08:16:01 root         INFO     Skipping 6002
08:16:01 root         INFO     Skipping 2505
08:16:01 root         INFO     Skipping 2000
08:16:01 root         INFO     Skipping 38456
08:16:01 root         INFO     Skipping 23099
08:16:01 root         INFO     Skipping 18560
08:16:01 root         INFO     Skipping 13255
08:16:01 root         INFO     Skipping 20676
08:16:01 root         INFO     Skipping 25743
08:16:01 root         INFO     Skipping 17989
08:16:01 root         INFO     Skipping 21452
08:16:01 root         INFO     Skipping 17224
08:16:01 root         INFO     Skipping 25875
08:16:01 root         INFO     Skipping 3486
08:16:02 root         INFO     Skipping 15377
08:16:02 root         INFO     Skipping 3418
08:16:02 root         INFO     Skipping 3492
08:16:02 root         INFO     Skipping 17990
08:16:02 root         INFO     Skipping 27184
08:16:02 root         INFO     Skipping 39590
08:16:02 root         INFO     Skipping 30767
08:16:02 root         INFO     Skipping 15022
08:16:02 root         INFO     Skipping 21452
08:16:02 root         INFO     Skipping 37309
08:16:02 root         INFO     Skipping 25730
08:16:02 root         INFO     Skipping 18418
08:16:03 root         INFO     Driver opened url https://www.gsk.com/en-gb/media/press-releases/: 0.5 second load started
08:16:04 root         INFO     Driver opened url https://www.gsk.com/en-gb/media/press-releases/depemokimab-accepted-for-review-by-the-european-medicines-agency-for-use-in-asthma/: 0.5 second load started
08:16:04 root         DEBUG    Titles: Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
08:16:04 root         DEBUG    Dates: 2025-01-28
08:16:04 root         DEBUG    Desc:   * If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing 

  * Submissions based on data from positive SWIFT and ANCHOR trials 

  * SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalisation rates as an add-on therapy for patients with asthma with type 2 inflammation 

  * ANCHOR-1 and -2 showed depemokimab reduced nasal polyp size and obstruction compared to placebo 




GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. 

The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on medium to high dose corticosteroids (ICS) plus another asthma controller and also as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). 

Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D,  said “Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for patients and health systems. Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress IL-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of their disease with just two doses per year.” 

Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory review for use in these conditions.  1  Depemokimab's extended half-life, high-binding affinity and potency, support six month (26 week) dosing regimens based on results from the SWIFT and ANCHOR trials.  1-3  In asthma patients and patients with CRSwNP, these trials showed depemokimab could offer sustained inhibition of a key driver of their disease, and help achieve key clinical outcomes with a dosing schedule of just two injections per year.  1-3  Longer intervals between doses have been shown to overcome barriers to optimal care such as patient adherence.  4 

IL-5 is a key cytokine (protein) in type 2 inflammation.  1,5,6  Type 2 inflammation is typically identified by blood eosinophil count and is an underlying driver in many diseases. This type of inflammation is present in the majority of patients with difficult to treat asthma and can lead to exacerbations and hospitalisation.  5-7  Type 2 inflammation is also present in up to 80% of people with CRSwNP and is associated with more severe disease and symptoms.  8-12 

In Europe, more than 42 million people are estimated to have asthma, which contributes to the significant burden this condition has on the lives of patients and healthcare resources, with an estimated annual societal cost of 46 billion euros.  13  CRSwNP is a chronic condition that affects up to 4% of the general population, of whom 40% have uncontrolled disease.  8,9,12 

Depemokimab is currently not approved in any country. 

##  About the depemokimab development programme 

The phase III asthma programme consists of SWIFT-1 and SWIFT-2 in asthma with type 2 inflammation, with an open label extension study (AGILE).  1,14  An additional study (NIMBLE) is underway to assess the efficacy and safety of depemokimab when participants with asthma with type 2 inflammation are switched from mepolizumab or benralizumab.  15 

The phase III programme in CRSwNP includes two studies, ANCHOR-1 and ANCHOR-2.  2,3 

Depemokimab is currently being evaluated in phase III trials for the treatment of other IL-5 mediated diseases, including OCEAN for eosinophilic granulomatosis with polyangiitis (EGPA)  16  and DESTINY for hypereosinophilic syndrome (HES).  17 

##  About SWIFT-1 and SWIFT-2 

SWIFT-1 and SWIFT-2 were replicate 52-week, randomised (2:1), double-blind, placebo-controlled, parallel-group, multi-centre Phase III clinical trials.  1  The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and adolescent participants with asthma with type 2 inflammation characterised by blood eosinophil count, who were randomised to receive depemokimab or placebo respectively, in addition to their standard of care treatment with medium to high-dose inhaled corticosteroids plus at least one additional controller.  1  Number of subjects included in the Full Analysis of SWIFT-1: depemokimab = 250, placebo = 132 and in SWIFT-2: depemokimab = 252, placebo = 128.1 

These results have been reported and published in the  New England Journal of Medicine  . 

##  About ANCHOR-1 and ANCHOR-2 

ANCHOR-1 and ANCHOR-2 were replicate phase III clinical trials with the same primary and secondary endpoints assessing the safety and efficacy of depemokimab as add-on therapy in adult patients with CRSwNP. Both were 52-week, randomised (1:1), double-blind, parallel group, placebo-controlled, multi-centre trials.  2,3  Number of subjects included in the Full Analysis Set of ANCHOR-1: depemokimab = 143, placebo = 128 and in ANCHOR-2: depemokimab = 129, placebo = 128. 

Both studies met their co-primary endpoints of change from baseline in total endoscopic nasal polyp score at 52 weeks and change from baseline in nasal obstruction verbal response scale (VRS) mean score from weeks 49 to 52. The overall incidence and severity of treatment-emergent adverse events across ANCHOR-1 and ANCHOR-2 were also similar in patients treated with either depemokimab or placebo. 

Full results of ANCHOR-1 and ANCHOR-2 will be presented at an upcoming scientific congress. 

##  About Asthma, CRSwNP and type 2 inflammation 

Asthma affects more than 260 million people globally many of whom continue to experience symptoms and exacerbations despite treatment with high-dose inhaled corticosteroids plus a second controller (and/or systemic corticosteroids).  5,18  Asthma presents a significant financial burden to patients as exacerbations place a resource burden on healthcare systems due to emergency department visits and hospitalisations.  18-20 

CRSwNP is caused by inflammation of the nasal lining that can lead to soft tissue growths, known as nasal polyps.  9,12  People with CRSwNP experience symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections and nasal discharge that can significantly affect their emotional and physical well-being.  9,12 

There is evidence to show IL-5 has broad effects on other structural and immune and cell types beyond eosinophils, and how they contribute to inflammation, which can lead to lung remodelling and disease progression.  5,6,21-25  Ongoing research is generating further evidence to understand the roles of these cells and their potential contribution to clinical outcomes in patients with respiratory diseases. Type 2 inflammation drives the underlying dysfunction of various immune-mediated conditions. IL-5 is a core cytokine (protein) in type 2 inflammation.  5,6  The presence of type 2 inflammation in asthma or CRSwNP can be detected by blood eosinophil count, which measures the level of a type of white blood cell.  5,8,12 

##  About GSK in respiratory 

GSK is redefining the future of respiratory medicine as it builds on decades of pioneering work to deliver more ambitious treatment goals and develop the next-generation standard of care, for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood diseases like refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim to modify underlying disease dysfunction and prevent disease progression. 

##  About GSK 

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. 

##  Cautionary statement regarding forward-looking statements 

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. 

08:16:04 root         DEBUG    Agency_id 17928
08:16:04 root         DEBUG    Article Link: https://www.gsk.com/en-gb/media/press-releases/depemokimab-accepted-for-review-by-the-european-medicines-agency-for-use-in-asthma/
08:16:04 root         INFO     LEDE: [testlede] month: [Jan.] day: [28]
08:16:04 root         INFO     
ADDING: FILENAME: [testfilename and CRSwNP] TITLE: [Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP] DATE: [2025-01-28] ID [17928]

08:16:05 root         INFO     Driver opened url https://www.gsk.com/en-gb/media/press-releases/depemokimab-applications-accepted-for-review-in-china-and-japan/: 0.5 second load started
08:16:06 root         DEBUG    Titles: Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
08:16:06 root         DEBUG    Dates: 2025-01-28
08:16:06 root         DEBUG    Desc:   * If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing 
  * Submissions based on data from positive SWIFT and ANCHOR trials 
  * SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalisation rates as an add-on therapy for patients with asthma with type 2 inflammation 
  * ANCHOR-1 and -2 showed depemokimab reduced nasal polyp size and obstruction compared to placebo 



GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare for use of depemokimab in two indications. 

In China, the submitted indications are for an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 and older with type 2 inflammation characterised by blood eosinophil count, and add-on maintenance treatment of adult patients with inadequately controlled CRSwNP. In Japan, the submitted indications are for treatment of severe or refractory bronchial asthma and CRSwNP inadequately controlled with standard treatment. 

Kaivan Khavandi  , SVP, Global Head of Respiratory/Immunology R&D,  said  “Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for patients and health systems. Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress IL-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of their disease with just two doses per year.” 

Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory review for use in these conditions.  1  Depemokimab's extended half-life, high-binding affinity and potency, support six month (26 week) dosing regimens based on results from the SWIFT and ANCHOR trials.  1-3  In asthma patients and patients with CRSwNP, these trials showed depemokimab could offer sustained inhibition of a key driver of their disease, and help achieve key clinical outcomes with a dosing schedule of just two injections per year.  1-3  Longer intervals between doses have been shown to overcome barriers to optimal care such as patient adherence.  4 

IL-5 is a key cytokine (protein) in type 2 inflammation.  1,5,6  Type 2 inflammation is typically identified by blood eosinophil count and is  an underlying driver in many diseases.  5  This type of inflammation is present in the majority of patients with difficult to treat asthma and can lead to exacerbations and hospitalisation.  5,7  Type 2 inflammation is also present in up to 80% of people with CRSwNP and is associated with more severe disease and symptoms.  8,12 

Asthma is a major health burden in China affecting an estimated 46 million adults with approximately 15.5% reporting to have experienced an exacerbation requiring a hospital visit in the last 12 months.  13 

CRSwNP is a chronic condition that affects up to 4% of the general population, of whom 40% have uncontrolled disease.  8,12,14  It is estimated that about 107 million people in China suffer from chronic sinusitis, about 1/3 of whom have chronic sinusitis with nasal polyps.  8,15-17  In Japan, it is estimated that there are 2 million people with chronic sinusitis, of which about 200,000 are subject to surgery due to nasal polyps.  18 

Depemokimab is currently not approved in any country. 

##  About the depemokimab development programme 

The phase III asthma programme consists of SWIFT-1 and SWIFT-2 in asthma with type 2 inflammation, with an open label extension study (AGILE).  1,19  An additional study (NIMBLE) is underway to assess the efficacy and safety of depemokimab when participants with asthma with type 2 inflammation are switched from mepolizumab or benralizumab.  20 

The phase III programme in CRSwNP includes two studies, ANCHOR-1 and ANCHOR-2.  2,3 

Depemokimab is currently being evaluated in phase III trials for the treatment of other IL-5  mediated diseases, including OCEAN for eosinophilic granulomatosis with polyangiitis (EGPA)  21  and DESTINY for hypereosinophilic syndrome (HES).  22 

##  About SWIFT-1 and SWIFT-2 

SWIFT-1 and SWIFT-2 were replicate 52-week, randomised (2:1), double-blind, placebo-controlled, parallel-group, multi-centre Phase III clinical trials.  1  The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and adolescent participants with asthma with  type 2 inflammation characterised by blood eosinophil count,  who were randomised to receive depemokimab or placebo respectively, in addition to their standard of care treatment with medium to high-dose inhaled corticosteroids plus at least one additional controller.  1  Number of subjects included in the Full Analysis of SWIFT-1: depemokimab = 250, placebo = 132 and in SWIFT-2: depemokimab = 252, placebo = 128.  1 

These results  have been reported and published in t  he  New England Journal of Medicine  . 

##  About ANCHOR-1 and ANCHOR-2 

ANCHOR-1 and ANCHOR-2 were replicate phase III clinical trials  with the same primary and secondary endpoints  assessing the safety and efficacy of depemokimab as add-on therapy in adult patients with CRSwNP. Both were 52-week, randomised (1:1), double-blind, parallel group, placebo-controlled, multi-centre trials.  2,3  Number of subjects included in the Full Analysis Set of ANCHOR-1: depemokimab = 143, placebo = 128 and in ANCHOR-2: depemokimab = 129, placebo = 128. 

Both studies met their co-primary endpoints of change from baseline in total endoscopic nasal polyp score at 52 weeks and change from baseline in nasal obstruction verbal response scale (VRS) mean score from weeks 49 to 52. The overall incidence and severity of treatment-emergent adverse events across ANCHOR-1 and ANCHOR-2 were also similar in patients treated with either depemokimab or placebo. 

Full results of ANCHOR-1 and ANCHOR-2 will be presented at an upcoming scientific congress. 

##  About Asthma, CRSwNP and type 2 inflammation. 

Asthma affects more than 260 million people globally many of whom continue to experience symptoms and exacerbations despite treatment with high-dose inhaled corticosteroids plus a second controller (and/or systemic corticosteroids).  5  ,23,24  Asthma presents a significant financial burden to patients as exacerbations place a resource burden on healthcare systems due to emergency department visits and hospitalisations.  5,24 

CRSwNP is caused by inflammation of the nasal lining that can lead to soft tissue growths, known as nasal polyps.  8,11  People with CRSwNP experience symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections and nasal discharge that can significantly affect their emotional and physical well-being.  8,11 

There is evidence to show IL-5 has broad effects on other structural and immune and cell types beyond eosinophils, and how they contribute to inflammation, which can lead to lung remodelling and disease progression.  5,6,25-29  Ongoing research is generating further evidence to understand the roles of these cells and their potential contribution to clinical outcomes in patients with respiratory diseases. Type 2 inflammation drives the underlying dysfunction of various immune-mediated conditions. IL-5 is a core cytokine (protein) in type 2 inflammation.  5,6  The presence of type 2 inflammation in asthma or CRSwNP can be detected by blood eosinophil count, which measures the level of a type of white blood cell.  ,5,8,12 

##  About GSK in respiratory 

GSK is redefining the future of respiratory medicine as it builds on decades of pioneering work to deliver more ambitious treatment goals and develop the next-generation standard of care, for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood diseases like refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim to modify underlying disease dysfunction and prevent disease progression. 

##  About GSK 

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. 

##  Cautionary statement regarding forward-looking statements 

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. 

##  References 

  1. Jackson DJ, et al. Six Monthly Depemokimab in Severe Asthma With an Eosinophilic Phenotype. NEJM. Published on September 9 at  org  . 
  2. gov. Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-1) Available at:  https://clinicaltrials.gov/study/NCT05274750  Accessed January 2025. 
  3. gov. Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) Available at:  https://clinicaltrials.gov/study/NCT05281523 Accessed January 2025  . 
  4. Scarsi KK, Swindells S. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?  Journal of the International Association of Providers of AIDS Care (JIAPAC)  . 2021;20. 
  5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention,2024. Updated May 2024. Available at:  https://ginasthma.org/  . Accessed January 2025. 
  6. Heaney L, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma  Chest  . 2021;160(3):814-830. 
  7. Principe S,  et al. S  evere asthma: Targeting the IL-5 pathway. Clin Exp Allergy. 2021 Aug;51(8):992-1005 
  8. Laidlaw TM, et al. Chronic Rhinosinusitis with Nasal Polyps and Asthma.  Allergy Clin. Immunol  . 2001;9(3):1133-1141. 
  9. Bachert C, et al. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps.  J Asthma Allergy  . 2021;b 11;14:127-134. doi: 10.2147/JAA.S290424. PMID: 33603409; PMCID: PMC7886239. 
  10. De Corso E, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review.  Acta Otorhinolaryngol Ital  . 2023;43(Suppl. 1):S3-S13. 
  11. Chen S, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.  Curr Med Res Opin  . 2020;36(11):1897-1911. 
  12. Bachert C, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management.  J Allergy Clin Immunol  . 2021;147(1):29-36. 
  13. Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. 2019; 394:407-418. 
  14. van der Veen J, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre.  Allergy  . 2017;72(2):282-290. 
  15. Liu Z, et al. Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis.  Allergy  Asthma Immunol Res  . 2020;12(2):176-237. 
  16. Wu Q, et al. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2021 Sep;11(9):e047344. 
  17. Wang Chengshuo, Zhang Luo. Biologics for the treatment of chronic rhinosinusitis with nasal polyps. Chinese Journal of Otolaryngology-Head and Neck Surgery, 2023, 58(3) : 193-199. 
  18. JESREC Study About refractory eosinophilic sinusitis available at  https://jesrec.jp/general/disease.html.  Accessed January 2025 
  19. gov. An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE). Available at:  https://clinicaltrials.gov/study/NCT05243680  Accessed January 2025. 
  20. gov. A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE). Available at:  https://clinicaltrials.gov/study/NCT04718389  Accessed January 2025. 
  21. gov. Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Available at:  https://clinicaltrials.gov/study/NCT05263934  Accessed January 2025. 
  22. gov. Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY) Available at:  https://clinicaltrials.gov/study/NCT05334368  Accessed January 2025. 
  23. World Health Organisation. Asthma Key Facts. Available at  https://www.who.int/news-room/fact-sheets/detail/asthma  Accessed January 2025 
  24. Israel, E,  et al.  Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med 2017;377:965-76. 
  25. Buchheit KM, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.  J Allergy Clin Immunol  . 2021;148(2):574-584. 
  26. Barretto KT, et al. Human airway epithelial cells express a functional IL-5 receptor.  Allergy  . 2020;75(8):2127-2130. 
  27. Bajbouj K, et al. IL-5 receptor expression in lung fibroblasts: Potential role in airway remodelling in asthma.  Allergy  . 2023;78(3):882-885. 
  28. Siddiqui S, et al. Eosinophils and tissue remodeling: Relevance to airway disease.  J Allergy Clin Immunol  . 2023;152(4):841-857. 
  29. Bergantini L, et al. Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab.  Scand J Immunol  . 2021;94(1):e13031. 



08:16:06 root         DEBUG    Agency_id 17928
08:16:06 root         DEBUG    Article Link: https://www.gsk.com/en-gb/media/press-releases/depemokimab-applications-accepted-for-review-in-china-and-japan/
08:16:06 root         INFO     LEDE: [testlede] month: [Jan.] day: [28]
08:16:06 root         INFO     
ADDING: FILENAME: [testfilename and CRSwNP] TITLE: [Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP] DATE: [2025-01-28] ID [17928]

08:16:06 root         ERROR    17928: 1062 (23000): Duplicate entry 'testfilename and CRSwNP' for key 'press_release.filename_uniq_idx'
08:16:07 root         INFO     Driver opened url https://www.gsk.com/en-gb/media/press-releases/gsk-and-oxford-establish-the-gsk-oxford-cancer-immuno-prevention-programme-to-advance-novel-cancer-research/: 0.5 second load started
08:16:07 root         DEBUG    Titles: GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
08:16:07 root         DEBUG    Dates: 2025-01-27
08:16:07 root         DEBUG    Desc:   * Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology 
  * GSK to invest up to £50 million in collaboration to generate key insights on how cancer develops that could inform future development of cancer vaccines 
  * Programme adds to existing relationship, including the ongoing GSK-Oxford Institute of Molecular and Computational Medicine 



GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer Immuno-Prevention Programme will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform new approaches to cancer vaccination. GSK will invest up to £50 million over a minimum of three years to support this early research. 

Evidence shows that most cancers take years or even decades to develop from normal cells to precancerous cells (or precancer) to cancer. Oxford University has world-leading expertise in the study of precancer biology including the identification and sequencing of neoantigens, or tumour-specific proteins that prompt the immune system to recognise cancer.  1  This unique focus could help target the vulnerabilities of precancerous cells through an active intervention like a vaccine or targeted medicine to prevent them from progressing to cancer. 

Tony Wood, Chief Scientific Officer, GSK, said  : “We’re pleased to further strengthen our relationship with Oxford University and to combine the deep knowledge of Oxford and GSK scientists. By exploring precancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer.” 

Professor Irene Tracey, Vice-Chancellor of the University of Oxford, said  : “This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.” 

Science and Technology Secretary, Peter Kyle, said:  “Cancer is a disease that has brought pain and heartbreak to every family in the country, including my own. But through our world-leading universities and businesses working in lockstep, like Oxford and GSK are doing here, we can harness science and innovation to transform what’s possible when it comes to diagnosing and treating this disease. As part of our Plan for Change, the Government is determined to back our £108 billion life sciences sector to deliver research like this – which could transform our health – whilst boosting our economy too.” 

Building on GSK’s ongoing relationship with Oxford, this collaboration will continue to combine GSK’s expertise in the science of the immune system and global development capability with Oxford’s cutting-edge research, clinical capabilities and world-leading scientists. 

In 2021, GSK and Oxford established the Institute of Molecular and Computational Medicine. The Institute, based at the University of Oxford, has demonstrated progress at improving the success and speed of research and development of new medicines, specifically in the field of neurodegeneration, building on insights from human genetics and using advanced technologies such as functional genomics and machine learning. 

##  About the University of Oxford 

Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the eighth year running, and number 3 in the QS World Rankings 2025. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer. 

Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions. 

##  About GSK 

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. 

##  Oxford enquiries 

For further information or to arrange an interview, please contact Christopher McIntyre, University of Oxford press office at news.office@admin.ox.ac.uk or on +44 (0)1865 280528. 

Interview opportunities are available with Professor Sarah Blagden, Professor of Experimental Oncology at the University of Oxford, who is the Oxford Director for the GSK-Oxford Cancer Immuno-Prevention Programme. 

##  Cautionary statement regarding forward-looking statements 

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. 

08:16:07 root         DEBUG    Agency_id 17928
08:16:07 root         DEBUG    Article Link: https://www.gsk.com/en-gb/media/press-releases/gsk-and-oxford-establish-the-gsk-oxford-cancer-immuno-prevention-programme-to-advance-novel-cancer-research/
08:16:07 root         INFO     LEDE: [testlede] month: [Jan.] day: [27]
08:16:07 root         INFO     
ADDING: FILENAME: [testfilename r research] TITLE: [GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research] DATE: [2025-01-27] ID [17928]

08:16:08 root         INFO     Driver opened url https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-european-medicines-agency/: 0.5 second load started
08:16:09 root         DEBUG    Titles: GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
08:16:09 root         DEBUG    Dates: 2025-01-27
08:16:09 root         DEBUG    Desc:   * If approved, the new presentation will offer a convenient administration option to healthcare professionals 

  * Globally, up to 1 in 3 adults will develop shingles in their lifetime  1,2,3,4 

  * Over 25 million people in Europe have received GSK’s shingles vaccine since 2018  5 




GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of  Shingrix  (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster). 

The new prefilled syringe removes the need to reconstitute separate vials prior to administration, offering a convenient option for physicians, pharmacists and other healthcare professionals who administer vaccinations. The current presentation of the vaccine consists of a lyophilised (powder) antigen and a liquid adjuvant, which healthcare professionals combine prior to administering. The new presentation has the same composition as the reconstituted vaccine and the submission is based on data demonstrating comparability between the two.  5 

This European regulatory review follows the file acceptance by the US FDA on 8 January 2025 for the new prefilled syringe presentation, continuing GSK’s commitment to providing solutions to increasing adult immunisation. GSK is also investigating submission of this presentation to other markets. GSK’s shingles vaccine has been approved in the European Union for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults aged 50 years and older since 2018; and in adults 18 years and older at increased risk of HZ, since 2020.  6 

##  About shingles 

Shingles typically presents as a rash, with painful blisters across the chest, abdomen or face.  7  Following the rash, up to 30% of people experience PHN  8  , a long-lasting nerve pain that can last weeks or months and can occasionally persist for several years.  1  Shingles is also associated with significant healthcare and human cost, with 57% of people with shingles reported missing work for an average of 9.1 days.  9 

Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox.  1  By age 50, VZV is present in most adults  10  and in some may reactivate with advancing age.  7  As people age, the strength of the immune system response to infection wanes, increasing the risk of developing shingles.  7 

##  About  Shingrix  (Recombinant Zoster Vaccine or RZV) 

Shingrix  (GSK’s Recombinant Zoster Vaccine or RZV) is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in adults 50 and over. It combines an antigen, glycoprotein E, with an adjuvant system, AS01B, and may help overcome the natural age-related decline in responses to immunisation that contributes to the challenge of protecting adults aged 50 and over from shingles.  11,12  RZV is not indicated to prevent primary varicella infection (chickenpox). In several countries, RZV is also approved for adults aged 18 years or over at increased risk for shingles. The use of RZV should be in accordance with official recommendations and local product label. 

Please refer to the Product Information (PI) for important dosage, administration, and safety information in Europe available at this link:  https://www.ema.europa.eu/en/medicines/human/EPAR/shingrix 

##  About GSK 

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. 

##  Cautionary statement regarding forward-looking statements 

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. 

##  References 

  1. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30. 
  2. Australian Institute of Health and Welfare. Shingles in Australia. Available at:  https://www.aihw.gov.au/getmedia/759199ff-f5c8-421d-a572-aaa984a02b49/aihw-phe-236_shingles.pdf.aspx  Last Accessed: November 2024. 
  3. Lee C, et al. Lifetime risk of herpes zoster in the population of Beijing, China. Public Health Pract (Oxf). 2023;5:100356. 
  4. Curran D, et al. Meta-Regression of Herpes Zoster Incidence Worldwide. Infect Dis Ther. 2022;11(1):389-403. 
  5. GSK data on file 2024. 
  6. Shingrix EU product information.  https://www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_en.pdf  Last accessed: November 2024. 
  7. Mueller, N.H., et al. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.  Neurologic clinics  . 2008;26(3):675-97. 
  8. Kawai, K., et al. Systematic review of incidence and complications of herpes zoster: towards a global perspective.  BMJ open  . 2014;4(6). 
  9. Rampakakis E, Stutz M, Kawai K, Tsai TF, Cheong HJ, Dhitavat J, et al. Association between work time loss and quality of life in patients with Herpes Zoster: a pooled analysis of the MASTER studies.  Health and Quality of Life Outcomes.  2017;15(1). 
  10. Johnson, R.W., et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic advances in vaccines. 2015;3(4):109–20. 
  11. Cunningham, AL, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. New England Journal of Medicine. 2016;375(11):1019–32. 
  12. The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. (NASDAQ: AGEN), MPL and liposomes. 



08:16:09 root         DEBUG    Agency_id 17928
08:16:09 root         DEBUG    Article Link: https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-european-medicines-agency/
08:16:09 root         INFO     LEDE: [testlede] month: [Jan.] day: [27]
08:16:09 root         INFO     
ADDING: FILENAME: [testfilename nes Agency] TITLE: [GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency] DATE: [2025-01-27] ID [17928]

08:16:10 root         INFO     Driver opened url https://www.gsk.com/en-gb/media/press-releases/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/: 0.5 second load started
08:16:10 root         DEBUG    Titles: European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
08:16:10 root         DEBUG    Dates: 2025-01-20
08:16:10 root         DEBUG    Desc:   * Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases 
  * Approval based on RUBY Part 1 trial, which showed a median overall survival (OS) of 44.6 months for  Jemperli  plus chemotherapy vs. 28.2 months for chemotherapy alone 
  * Jemperli  plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population 



GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved  Jemperli  (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This approval broadens the previous indication for  Jemperli  plus chemotherapy in the European Union (EU) to include patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, which represent approximately 75% of patients diagnosed with endometrial cancer and who have limited treatment options. 

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said  : “For the first time, all patients with primary advanced or recurrent endometrial cancer in the EU have an approved immuno-oncology-based treatment that has shown a statistically significant and clinically meaningful overall survival benefit. We’re proud  Jemperli  continues to redefine the treatment landscape for patients.” 

Dr Mansoor Raza Mirza, Chief Oncologist, Copenhagen University Hospital, Denmark, and RUBY principal investigator said  : “Clinicians have been waiting for years for an immuno-oncology-based option that can meaningfully improve overall survival outcomes for patients with MMRp/MSS primary advanced or recurrent endometrial cancer. The expanded approval represents a significant advance that delivers on this hope, now for patients with both dMMR/MSI-H and MMRp/MSS tumours.” 

The European Commission’s approval to expand the use of  Jemperli  plus chemotherapy is based on results from Part 1 of the RUBY phase III trial. RUBY Part 1 is the only clinical trial in this setting to show a clinically meaningful and statistically significant overall survival (OS) benefit in the full population of patients with primary advanced or recurrent endometrial cancer, demonstrating a 31% reduction in risk of death (HR: 0.69; 95% CI: 0.54–0.89) compared to chemotherapy alone. 

At the 2.5-year landmark, the chance of being alive was 61% (95% CI: 54-67) for patients in the  Jemperli  plus chemotherapy group (245 patients) compared to 49% (95% CI: 43-55) in the chemotherapy group (249 patients). In addition, a 16.4-month improvement in median OS was observed with  Jemperli  plus chemotherapy versus chemotherapy alone (44.6 months [95% CI: 32.6–NR] vs. 28.2 months [95% CI: 22.1–35.6], respectively). The median duration of follow-up was more than three years.  1  The safety and tolerability analysis from RUBY Part 1 showed a safety profile for  Jemperli  plus carboplatin-paclitaxel that was generally consistent with the known safety profiles of the individual agents. The most common treatment-emergent adverse reactions (\u2265 10%) in patients receiving  Jemperli  plus chemotherapy were rash, rash maculopapular, hypothyroidism, pyrexia, alanine aminotransferase increased, aspartate aminotransferase increased and dry skin. 

OS data were  presented  at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer on 16 March 2024, and were published in  Annals of Oncology  on 9 June 2024. The label for  Jemperli  plus chemotherapy in the US was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. 

##  About endometrial cancer 

Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. Endometrial cancer is the most common gynaecologic cancer in developed countries,  2  with an estimated 1.6 million people living with active disease at any stage and 417,000 new cases reported each year worldwide.  3  Incidence rates are expected to rise by approximately 40% between 2020 and 2040.  4  In Europe, approximately 121,000 people are estimated to be diagnosed with primary advanced or recurrent endometrial cancer each year.  5  Approximately 15-20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.  6  Among patients with primary advanced or recurrent endometrial cancer, approximately 75% have MMRp/MSS tumours.  7 

##  About RUBY 

RUBY is a two-part global, randomised, double-blind, multicentre phase III trial of 785 patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo. Part 2 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo.   
  
In Part 1, the dual-primary endpoints are investigator-assessed progression-free survival (PFS) based on the Response Evaluation Criteria in Solid Tumours v1.1 and OS. The statistical analysis plan included pre-specified analyses of PFS in the mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and overall populations and OS in the overall population. Pre-specified exploratory analyses of PFS and OS in the MMRp/MSS population and OS in the dMMR/MSI-H populations were also performed. RUBY Part 1 included a broad population, including histologies often excluded from clinical trials and had approximately 10% of patients with carcinosarcoma and 20% with serous carcinoma.   
  
In Part 2, the primary endpoint is investigator-assessed PFS in the overall population, followed by PFS in the MMRp/MSS population, and OS in the overall population is a key secondary endpoint. Additional secondary endpoints in Part 1 and Part 2 include PFS per blinded independent central review, PFS2, overall response rate, duration of response, disease control rate, patient-reported outcomes, and safety and tolerability.   
  
RUBY is part of an international collaboration between the European Network of Gynaecological Oncological Trial groups (ENGOT), a research network of the European Society of Gynaecological Oncology (ESGO) that consists of 22 trial groups from 31 European countries that perform cooperative clinical trials, and the GOG Foundation, a non-profit organisation dedicated to transforming the standard of care in gynaecologic oncology. 

##  About  Jemperli  (dostarlimab) 

Jemperli  , a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes studies of Jemperli alone and in combination with other therapies in gynaecologic, colorectal and lung cancers, as well as where there are opportunities for transformational outcomes. 

In the US,  Jemperli  is indicated in combination with carboplatin and paclitaxel, followed by  Jemperli  as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This includes patients with MMRp/MSS and dMMR/MSI-H tumours.  Jemperli  is also approved as a single agent for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. Additionally,  Jemperli  is indicated in the US for patients with dMMR recurrent or advanced solid tumours, as determined by a US FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. The latter indication is approved in the US under accelerated approval based on tumour response rate and durability of response. Continued approval for this indication in solid tumours may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).   
  
Jemperli  was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a collaboration and exclusive license agreement signed in March 2014. Under this agreement, GSK is responsible for the ongoing research, development, commercialisation, and manufacturing of Jemperli and cobolimab (GSK4069889), a TIM-3 antagonist. 

##  Important Information for  Jemperli  in the EU 

###  Indication 

Jemperli  is indicated: 

  * in combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy; 
  * as monotherapy for treating adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. 



Refer to the  Jemperli  EMA Reference Information  for a full list of adverse events and the complete important safety information in the EU. 

##  GSK in oncology 

Oncology is an emerging therapeutic area for GSK where we are committed to maximising patient survival with a current focus on haematologic malignancies, gynaecologic cancers, and other solid tumours through breakthroughs in immuno-oncology and tumour-cell targeting therapies. 

##  About GSK 

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. 

##  Cautionary statement regarding forward-looking statements 

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. 

08:16:10 root         DEBUG    Agency_id 17928
08:16:10 root         DEBUG    Article Link: https://www.gsk.com/en-gb/media/press-releases/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
08:16:10 root         INFO     LEDE: [testlede] month: [Jan.] day: [20]
08:16:10 root         INFO     
ADDING: FILENAME: [testfilename ial cancer] TITLE: [European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer] DATE: [2025-01-20] ID [17928]

08:16:11 root         INFO     Driver opened url https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-idrx-inc/: 0.5 second load started
08:16:11 root         DEBUG    Titles: GSK enters agreement to acquire IDRx, Inc.
08:16:11 root         DEBUG    Dates: 2025-01-13
08:16:11 root         DEBUG    Desc:   * Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) 
  * IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies 
  * Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers 
  * GSK to pay up to $1.15 billion 



GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. 

GIST typically presents in the GI tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation, and survival of tumour cells (primary or activating mutations).  1  90% of patients treated in the first-line develop new KIT mutations (secondary or resistance mutations) that typically lead to relapse with limited therapeutic options.  2  Currently, there are no approved TKIs that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT. 

IDRX-42 has demonstrated activity against all key primary and secondary KIT mutations, designed to improve outcomes for patients with GIST. This breadth of mutational coverage, in addition to high selectivity which could improve tolerability, provides potential for a best-in-class profile. 

Luke Miels, Chief Commercial Officer, GSK, said:  “IDRX-42 complements our growing portfolio in gastrointestinal cancers. This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products.” 

Tony Wood, Chief Scientific Officer, GSK, said:  “We are excited by the early data from IDRX-42 and its unique ability to target all clinically relevant KIT mutations present in GIST, a major gap in the current standard of care. We look forward to accelerating its development in 2025 to redefine treatment.” 

Updated clinical data from StrateGIST 1, an ongoing phase I/Ib trial of IDRX-42 in patients with advanced GIST, were presented in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting. These data show promising anti-tumour activity of IDRX-42 in patients with advanced GIST with a manageable safety profile. Across patients with second-line or greater GIST, and amongst all KIT mutation subsets, the objective response rate (ORR) by modified RECIST v1.1 in the total efficacy evaluable population was 29% (n=87), including one complete response (CR) and 24 partial responses (PRs). Amongst patients who have had one prior line of therapy, the ORR was 53% (n=15) including one CR and 7 PRs.  3 

Across all patients, two of the PRs were awaiting confirmation at the time of the data cut, both of which were subsequently confirmed. The emerging durability data from StrateGIST 1 was also favourable. IDRX-42 was generally well-tolerated and treatment-related adverse events (TRAEs) were mainly low grade at the recommended phase Ib dose.  4 

Tim Clackson, CEO, IDRx, said:  “We are looking forward to working with GSK to advance IDRX-42 for patients with GIST given there have been no major advances to the standard of care for almost 20 years. Combining our experience to date with GSK’s expertise in GI cancers, global clinical development capability, and strong commercial presence in oncology will help to accelerate the development of this novel medicine for patients.” 

GSK has a growing portfolio in development targeting the significant medical need in GI cancers, including ongoing trials with dostarlimab and GSK5764227 (GSK’227), a B7-H3-targeted antibody-drug conjugate. This agreement reflects GSK’s portfolio approach of identifying potentially best-in-class molecules with targeted mechanisms of action. The transaction supports GSK’s ambitions for growth through 2031 and beyond. 

##  Financial considerations 

Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up to $1.15 billion of total cash consideration, comprising an upfront payment of $1 billion with potential for an additional $150 million success-based regulatory approval milestone payment. GSK will also be responsible for success-based milestone payments as well as tiered royalties for IDRX-42 owed to Merck KGaA, Darmstadt, Germany. 

This transaction is subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US. 

For IDRx, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP as legal counsel. For GSK, Leerink Partners LLC is acting as the exclusive financial advisor. 

##  About GIST 

Gastrointestinal stromal tumours (GIST) are the most common subtype of soft tissue sarcoma, with about 80,000 to 120,000 patients diagnosed with GIST per year worldwide.  5  GIST typically presents in the GI tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation, and survival of tumour cells (primary or activating mutations in exons 9 and 11).  6  Additionally, about 90% of patients treated in the first-line develop new KIT mutations (secondary or resistance mutations in exons 13 and 17) that typically lead to relapse with limited therapeutic options.  7  There are no approved TKIs that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT. 

##  About IDRX-42 

IDRX-42 is a highly selective, investigational small molecule tyrosine kinase inhibitor (TKI) designed to target all key KIT mutations in GIST. The U.S. Food and Drug Administration (FDA) has granted IDRX-42 Fast Track designation for the treatment of patients with GIST after disease progression on or intolerance to imatinib, and Orphan Drug designations for the treatment of GIST. 

##  About IDRx 

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumour escape mechanisms and prolong response to therapy. 

##  About GSK 

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. 

##  Cautionary statement regarding forward-looking statements 

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. 

08:16:11 root         DEBUG    Agency_id 17928
08:16:11 root         DEBUG    Article Link: https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-idrx-inc/
08:16:11 root         INFO     LEDE: [testlede] month: [Jan.] day: [13]
08:16:11 root         INFO     
ADDING: FILENAME: [testfilename IDRx, Inc.] TITLE: [GSK enters agreement to acquire IDRx, Inc.] DATE: [2025-01-13] ID [17928]

08:16:11 root         INFO     INVALID DATE: 2025-10-01 00:00:00
08:16:11 root         INFO     INVALID DATE: 2025-07-01 00:00:00
08:16:11 root         INFO     INVALID DATE: 2025-03-01 00:00:00
08:16:11 root         INFO     INVALID DATE: 2024-12-20 00:00:00
08:16:11 root         INFO     INVALID DATE: 2024-12-16 00:00:00
08:16:12 root         INFO     Scrape errors found during run:
08:16:12 root         INFO     []
08:16:12 root         INFO     End of file message
08:16:12 root         INFO     

Load Version 2.1.0 01/28/2025
       Docs Loaded: 5
       URLS processed: 1
       DUPS skipped: 1
       No Ledes found: 0

Passed Parameters:
       Pull House and Senate: False
       Number of days back: 30
       Start Time: 2025-01-29 08:15:57
       End Time: 2025-01-29 08:16:12
       Elapsed Time: 0:00:14
       Character Minimum Amount: 100

Errors:
Docs:
	Loaded:
		17928: Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
		17928: GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
		17928: GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
		17928: European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
		17928: GSK enters agreement to acquire IDRx, Inc.
	Duplicates:
		17928: Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
